News

Long-term treatment with Vyvgart (efgartigimod alfa-fcab) is safe and well tolerated, and leads to a sustained improvement in generalized myasthenia gravis (gMG) disease scores. These findings come from an interim analysis of ADAPT+ (NCT03770403), an ongoing Phase 3, open-label, three-year extension of ADAPT (NCT03669588) that is…

Treatment with Ultomiris (ravulizumab-cwvz) eased symptoms of generalized myasthenia gravis (gMG) for more than a year, according to new data from the ongoing CHAMPION-MG extension study. Findings were shared at the 2022 American Academy of Neurology (AAN) Annual Meeting in an oral presentation, titled “Long-term Efficacy and Safety of…

More or larger clusters of developing B-cells, called germinal centers, in the thymus may predict better outcomes after thymus removal surgery in people with myasthenia gravis (MG), according to a recent study that utilized modern tools of digital pathology to support its findings. “Digital pathology can thus help in…

Myasthenia gravis (MG) may occur alongside Miller Fisher syndrome, another rare autoimmune disease also characterized by weakness of the eye muscles, a recent case report highlights. The report emphasizes the importance of careful examination for the possibility of co-occurring autoimmune disorders when a patient shows uncommon symptoms. “Even…

Many people with myasthenia gravis (MG) caused by antibodies against MuSK initially present with eye-related symptoms, which soon affect other parts of the body, according to a new study. “The present study provides a better understanding of MuSK-MG disease and its clinical course,” its researchers wrote. The study, “…

Healthcare providers involved in diagnosing and treating rare diseases believe that increased physician education and collaboration with specialized facilities will have the greatest positive impact on treating these conditions over the next five years, according to results from a 2021 survey. Definitive Healthcare, a healthcare commercial intelligence company, conducted…

An under-the-skin injection formulation of efgartigimod is as effective as the therapy’s infusion version, sold as Vyvgart (efgartigimod alfa-fcab), at lowering immunoglobulin G antibody levels in people with generalized myasthenia gravis (gMG), according to top-line data from the ADAPT-SC trial. Based on these findings, Argenx, the therapy’s developer, plans…

This year’s MGNet Scholar award, funded by the Myasthenia Gravis Rare Disease Network (MGNet), has gone to a scientist at Yale University who is investigating the immune mechanisms behind the development of myasthenia gravis (MG) in people who have been treated with a type of immunotherapy. The awardee…

Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities and connecting with researchers. Eric Sid, MD, program officer for the Office of Rare Diseases Research (ORDR), said it is difficult to estimate how…

Soliris (eculizumab) is better than rituximab at controlling myasthenia gravis (MG) symptoms over a two-year period, according to a new analysis. Results were detailed in the study, “Eculizumab versus rituximab in generalised myasthenia gravis,” published in the Journal of Neurology, Neurosurgery and Psychiatry. Soliris…